Intravitreal injection of bevacizumab: Changes in intraocular pressure related to ocular axial length

Japanese Journal of Ophthalmology

Volumn 57, Issue 1, 2013, Pages 63-67

  Cacciamani, Andrea ^a   Oddone, Francesco ^a   Parravano, Mariacristina ^a   Scarinci, Fabio ^a   Di Nicola, Marta ^b   Lofoco, Giorgio ^c  

^a IRCCS FONDAZIONE BIETTI   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Intraocular drugs; Intraocular pressure; Intravitreal injection

Indexed keywords

BEVACIZUMAB;

AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; DISEASE ASSOCIATION; EYE AXIS LENGTH; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; OPHTHALMOLOGY; PATIENT REFERRAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; TONOMETRY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AXIAL LENGTH, EYE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TONOMETRY, OCULAR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84872619488     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-012-0194-8     Document Type: Article

References (22)

1. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-9.
2. Rl Avery, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-72.
3. Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularisation in pathologic myopia. Retina. 2006;26:1093-4.
4. Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand. 2007;85:777-81.
5. Frenkel REP, Mani L, Toler AR, Frenkel MPC. Intraocular pressure effects of Pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007;143:1034-5.
6. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2009;23:181-5.
7. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146:930-4.
8. Wu H, Chen TC. The effects of intravitreal ophthalmic medications on intraocular pressure. Semin Ophthalmol. 2009;24:100-5.
9. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2007;27:1044-7.
10. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007;42:807-11.
11. Utman SA, Dhillon B. Comment on: changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2008;28:667.
12. Tsui YP, Chiang CC, Tsai YY. Paracentesis before intravitreal injection of bevacizumab. Can J Ophthalmol. 2008;43:239.
13. Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arc Ophthalmol. 2010;128:1523-7.
14. Kim KS, Jee D. Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique. Jpn J Ophthalmol. 2011;55:632-7.
15. Ueda T, Nawa Y, Hara Y. Relationship between the retinal thickness of the macula and the difference in axial length. Graefes Arch Clin Exp Ophthalmol. 2006;244:498-501.
16. Kojima T, Tamaoki A, Yoshida N, Kaga T, Suto C, Ichikawa K. Evaluation of axial length measurement of the eye using partial coherence interferometry and ultrasound in cases of macular disease. Ophthalmology. 2010;117:1750-4.
17. Guidelines for performing intravitreal therapy. The Royal Australian and New Zealand College of Ophthalmologists. 2006.
18. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusin P. Short-term effect of intravitreal injection of ranibizumab (lucentis) on intraocular pressure. J Glaucoma. 2009;18:658-61.
19. Boon CJF, Crama N, Klevering BJ, van Kuijk FJ, Hoyng CB. Reflux after intravitreal injection of bevacizumab. Ophthalmology. 2008;115:1270.
20. Pallikaris IG, Kymionis GD, Ginis HS, Kounis GA, Tsilimbaris MK. Ocular rigidity in living human eyes. Invest Ophthalmol Vis Sci. 2005;45:409-14.
21. Pallikaris IG, Kymionis GD, Ginis SH, Kounis GA, Christodoulakis E, Tsilimbaris MK. Ocular rigidity in patients with age related macular degeneration. Am J Ophthalmol. 2006;141:611-5.
22. Kerimoglu H, Ozturk BT, Bozkurt B, Okka M, Okudan S. Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? Acta Ophthalmol. 2011;89:138-42.